Patents by Inventor Sandra Boccard

Sandra Boccard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Sensizitation of cancer cells to therapy using sina targeting genes from the 1P and 19Q chromosomal regions
    Patent number: 8293886
    Abstract: The invention relates to the identification of genes involved in resistance of cancer cells to therapy, to short nucleic acid molecules which inhibit the expression of these genes by RNA interference and to their use as adjuvant in cancer therapy, to sensitize cancer cells to conventional anticancer agents; the short nucleic acid molecules are double-stranded short interfering nucleic acid molecules including a sense and an antisense region, wherein the sense region includes a nucleotide sequence that is selected from the group consisting of: the sequences SEQ ID NO: 15, 11, 13, 14, 30, 31, 38, 46, 64 and 70 and the sequences having at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity with the sequences, and the antisense region includes a nucleotide sequence that is complementary to the sense region.
    Type: Grant
    Filed: March 22, 2011
    Date of Patent: October 23, 2012
    Assignee: Universite Joseph Fourier
    Inventors: Francois Berger, Laurent Pelletier, Jean-Paul Issartel, Sandra Boccard
  • SENSIZITATION OF CANCER CELLS TO THERAPY USING SINA TARGETING GENES FROM THE 1P AND 19Q CHROMOSOMAL REGIONS
    Publication number: 20110294867
    Abstract: The invention relates to the identification of genes involved in resistance of cancer cells to therapy, to short nucleic acid molecules which inhibit the expression of these genes by RNA interference and to their use as adjuvant in cancer therapy, to sensitize cancer cells to conventional anticancer agents; the short nucleic acid molecules are double-stranded short interfering nucleic acid molecules including a sense and an antisense region, wherein the sense region includes a nucleotide sequence that is selected from the group consisting of: the sequences SEQ ID NO: 15, 11, 13, 14, 30, 31, 38, 46, 64 and 70 and the sequences having at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity with the sequences, and the antisense region includes a nucleotide sequence that is complementary to the sense region.
    Type: Application
    Filed: March 22, 2011
    Publication date: December 1, 2011
    Applicant: UNIVERSITE JOSEPH FOURIER
    Inventors: Fran+525 ois BERGER, Laurent PELLETIER, Jean-Paul ISSARTEL, Sandra BOCCARD
  • Sensizitation of cancer cells to therapy using siNA targeting genes from the 1p and 19q chromosomal regions
    Patent number: 7939653
    Abstract: The invention relates to the identification of genes involved in resistance of cancer cells to therapy, to short nucleic acid molecules which inhibit the expression of these genes by RNA interference and to their use as adjuvant in cancer therapy, to sensitize cancer cells to conventional anticancer agents; the short nucleic acid molecules are double-stranded short interfering nucleic acid molecules including a sense and an antisense region, wherein the sense region includes a nucleotide sequence that is selected from the group consisting of: the sequences SEQ ID NO: 15, 11, 13, 14, 30, 31, 38, 46, 64 and 70 and the sequences having at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity with the sequences, and the antisense region includes a nucleotide sequence that is complementary to the sense region.
    Type: Grant
    Filed: July 23, 2007
    Date of Patent: May 10, 2011
    Assignee: Universite Joseph Fourier
    Inventors: François Berger, Laurent Pelletier, Jean-Paul Issartel, Sandra Boccard
  • SENSIZITATION OF CANCER CELLS TO THERAPY USING SINA TARGETING GENES FROM THE 1P AND 19Q CHROMOSOMAL REGIONS
    Publication number: 20100076054
    Abstract: The invention relates to the identification of genes involved in resistance of cancer cells to therapy, to short nucleic acid molecules which inhibit the expression of these genes by RNA interference and to their use as adjuvant in cancer therapy, to sensitize cancer cells to conventional anticancer agents; the short nucleic acid molecules are double-stranded short interfering nucleic acid molecules including a sense and an antisense region, wherein the sense region includes a nucleotide sequence that is selected from the group consisting of: the sequences SEQ ID NO: 15, 11, 13, 14, 30, 31, 38, 46, 64 and 70 and the sequences having at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity with the sequences, and the antisense region includes a nucleotide sequence that is complementary to the sense region.
    Type: Application
    Filed: July 23, 2007
    Publication date: March 25, 2010
    Applicant: UNIVERSITE JOSEPH FOURIER
    Inventors: Francois Berger, Laurent Pelletier, Jean-Paul Issartel, Sandra Boccard